Pharmaceutical News

RSS

Study shows amphetamines can keep exhaustion at bay in male rats

Indiana University researchers put male rats to the test to determine the role amphetamines play when used in conjunction with exercise.

29 May 2014

Study shows high BP drugs may raise likelihood of age-related macular degeneration

There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology.

29 May 2014

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

29 May 2014

FDA postpones Dispute Resolution Panel for FzioMed’s Oxiplex PMA

FzioMed, Inc. today announced it has agreed with the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) to postpone the Dispute Resolution Panel for its Oxiplex PMA; the meeting was previously scheduled for June 10.z

28 May 2014

Trimel announces top-line results of Phase II clinical trial evaluating efficacy of Tefina

Trimel Pharmaceuticals Corporation (TSX: TRL) announced today top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina™, a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD).

28 May 2014

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

28 May 2014

Critically ill patients receiving steroids in ICU are more likely to develop delirium

New Johns Hopkins research suggests that critically ill patients receiving steroids in a hospital’s intensive care unit (ICU) are significantly more likely to develop delirium. Results of their research, they say, suggest minimizing the use of steroids could reduce delirium in the ICU.

28 May 2014

Commonly used diabetes medications may also have positive effects against cancer cell proliferation

One of the most commonly used medications to control diabetes may also have positive effects against cancer cell proliferation, as show in research done at the Center for Research and Advanced Studies (CINVESTAV) in Mexico.

28 May 2014

Findings may help medical researchers identify effective drug targets for triple negative breast cancer

The suppression of two genes reduce breast cancer tumor formation and metastasis by interfering with blood vessel formation and recruitment, report scientists from Houston Methodist and five other institutions in the Proceedings of the National Academy of Sciences (now online).

28 May 2014

Patients receiving steroids in hospital's ICU more likely to develop delirium, says study

New Johns Hopkins research suggests that critically ill patients receiving steroids in a hospital's intensive care unit (ICU) are significantly more likely to develop delirium. Results of their research, they say, suggest minimizing the use of steroids could reduce delirium in the ICU.

28 May 2014

Case Western Reserve physician calls on FDA to address hidden risk of dangerous drugs side effects

The agency charged to protect patients from dangerous drug side effects needs to be far more vigilant when it comes to medications that affect blood pressure.

28 May 2014

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect.

27 May 2014

FDA issues Complete Response Letter to QRxPharma regarding Moxduo NDA

QRxPharma Limited announced today the United States Food and Drug Administration has issued a Complete Response Letter regarding the Moxduo New Drug Application for the treatment of moderate to severe acute pain.

27 May 2014

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Octapharma confirmed today the European Medicines Agency (EMA) has adopted a positive opinion towards human cell line recombinant human FVIII, Nuwiq®, recommending the granting of a marketing authorisation for the medicinal product for treatment and prophylaxis of bleeding (also during and after surgery) in paediatric and adult patients with haemophilia A (congenital FVIII deficiency).

27 May 2014

Alligator Bioscience acquires rights to drug development candidate ADC-1013

BioInvent International AB (publ) (OMXS:BINV) today announced that the company has sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum.

27 May 2014

Abiogen Pharma, Lee's Pharma sign deal to market Neridronic Acid

Abiogen Pharma S.p.A. of Pisa Italy and Lee's Pharm jointly announced the agreement for License, Distribution and Supply for marketing of Attila® (Neridronic Acid) throughout China, Hong Kong, Macau and Taiwan.

27 May 2014

Estrogen therapy and venlafaxine treatment effective for hot flashes, night sweats

A new research study from Brigham and Women's Hospital (BWH) that compares low-dose oral estrogen and low-dose non-hormonal venlafaxine hydrochloride extended release (XR) to placebo were both found effective in reducing the number of hot flashes and night sweats reported by menopausal women.

27 May 2014

Pharmaceutical News

Study shows amphetamines can keep exhaustion at bay in male rats

Study shows high BP drugs may raise likelihood of age-related macular degeneration

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

FDA postpones Dispute Resolution Panel for FzioMed’s Oxiplex PMA

Trimel announces top-line results of Phase II clinical trial evaluating efficacy of Tefina

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Critically ill patients receiving steroids in ICU are more likely to develop delirium

Commonly used diabetes medications may also have positive effects against cancer cell proliferation

Findings may help medical researchers identify effective drug targets for triple negative breast cancer

Patients receiving steroids in hospital's ICU more likely to develop delirium, says study

Case Western Reserve physician calls on FDA to address hidden risk of dangerous drugs side effects

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

FDA issues Complete Response Letter to QRxPharma regarding Moxduo NDA

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Alligator Bioscience acquires rights to drug development candidate ADC-1013

Abiogen Pharma, Lee's Pharma sign deal to market Neridronic Acid

Estrogen therapy and venlafaxine treatment effective for hot flashes, night sweats

Employers to implement mandatory influenza vaccination policies for health care workers

McGill researchers show melatonin supplements may make bones stronger in old rats

Researchers discover novel enzyme that promotes insulin secretion in type 2 diabetes animal model

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News